**Biomarkers** 

# The Association Between Cortisol Response to Mental Stress and High-Sensitivity Cardiac Troponin T Plasma Concentration in Healthy Adults

Antonio I. Lazzarino, MD, MSc,\* Mark Hamer, PHD,\* David Gaze, PHD,† Paul Collinson, MD,† Andrew Steptoe, DSc\*

London, United Kingdom

Objectives	The objective of this study was to examine the association between cortisol response to mental stress and high- sensitivity cardiac troponin T (hs-cTnT) in healthy older individuals without history of cardiovascular disease (CVD).
Background	Mental stress is a recognized risk factor for CVD, although the mechanisms remain unclear. Cortisol, a key stress hormone, is associated with coronary atherosclerosis and may accentuate structural and functional cardiac disease.
Methods	This cross-sectional study involved 508 disease-free men and women aged 53 to 76 years drawn from the Whitehall Il epidemiological cohort. We evaluated salivary cortisol response to standardized mental stress tests (exposure) and hs-cTnT plasma concentration using a high-sensitivity assay (outcome). We measured coronary calcification using electron-beam dual-source computed tomography and Agatston scores.
Results	After adjustment for demographic and clinical variables associated with CVD as well as for inflammatory factors, we found a robust association between cortisol response and detectable hs-cTnT (odds ratio [OR]: 3.98; 95% confidence interval [Cl]: 1.60 to 9.92; $p = 0.003$ ). The association remained when we restricted the analysis to participants without coronary calcification ( $n = 222$ ; OR: 4.77; 95% Cl: 1.22 to 18.72; $p = 0.025$ ) or when we further adjusted for coronary calcification in participants with positive Agatston scores ( $n = 286$ ; OR: 7.39; 95% Cl: 2.22 to 26.24; $p = 0.001$ ).
Conclusions	We found that heightened cortisol response to mental stress was associated with detectable plasma levels of cTnT using high-sensitivity assays in healthy participants, independently of coronary atherosclerosis. Further research is needed to understand the role of psychosocial stress in the pathophysiology of cardiac cell damage. (J Am Coll Cardiol 2013;62:1694–701) © 2013 by the American College of Cardiology Foundation

Mental stress is becoming increasingly recognized as a risk factor and trigger for cardiovascular disease (CVD) events (1–3). Stress can be studied in several ways, including epidemiological studies, laboratory-based psychophysiological testing, and animal research. Psychophysiological testing allows mechanisms to be studied by measuring biological responses to standardized behavioral challenge. Stress markers relevant to CVD include proinflammatory factors, cortisol level, heart rate variability, and hemostatic processes (4,5). Mental stress initiates the release of cortisol by activating corticotropin-releasing factor and arginine vasopressin neurons in the paraventricular nucleus of the hypothalamus (6). This leads to the release of adrenocorticotropic hormone from the pituitary

gland, which triggers release of glucocorticoids from the adrenal glands. Cortisol has attracted relatively little attention as a mechanism linking stress and CVD. However, several population studies have demonstrated associations between diurnal cortisol patterns and subclinical atherosclerosis (7,8).

#### See page 1702

Additionally, a flatter slope in the decline of cortisol levels across the day (thought to be a marker of chronic stress) is associated with an increased risk of CVD mortality in British civil servants (9); 24-h urinary cortisol level was associated with CVD death in the InCHIANTI (Invecchiare [Aging] in Chianti [region in Italy]) prospective cohort study of older people (10); serum cortisol levels were found to be a cardiac event risk predictor in patients with chronic heart failure; and cardiac event prediction based on cortisol levels was influenced by oxidative stress (11). Recent data from our laboratory have shown that heightened increases in salivary cortisol levels

From the \*Department of Epidemiology and Public Health, University College London, London, United Kingdom; and †Chemical Pathology, Clinical Blood Sciences, St. George's Healthcare NHS Trust, London, United Kingdom. This research was supported by the British Heart Foundation and the Medical Research Council, United Kingdom. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Manuscript received April 24, 2013; accepted May 7, 2013.

following standardized mental stress tests in healthy older individuals were associated with greater coronary artery calcification (CAC) and with CAC progression over 3 years (12,13).

Cardiac troponin T (cTnT) is a plasma protein routinely used for the diagnosis of acute myocardial infarction (AMI) (14,15). In clinical settings cTnT is measured using standard assays that have a detection limit of 10 ng/l (16) and a diagnostic threshold of 35 ng/l (14,15). However, high-sensitivity assays (hs-cTnT) have now been developed with a lower detection limit of 3 ng/l (17-19). In healthy people not fulfilling any diagnostic criteria for AMI, greater hs-cTnT level is associated with a greater incidence of structural and functional heart disease, cardiovascular mortality, and allcause mortality (20,21). Among patients undergoing noncardiac surgery, the post-operative increase in hs-cTnT plasma concentration was associated with increased 30-day mortality (22). In a study of community-derived perimenopausal women, hs-cTnT level was associated with long-term mortality, independently of amino-terminal pro-B-type natriuretic peptide and other risk factors (23).

Cortisol is associated with coronary atherosclerosis, although whether this hormone plays a role in structural and functional cardiac disease remains unclear. The aim of our study was therefore to provide further insight into the role of cortisol in CVD by examining the association between cortisol responses to mental stress and hs-cTnT concentrations in healthy older individuals without a history of CVD, taking into account underlying coronary atherosclerosis. We hypothesized that high cortisol responders are individuals who are hyperreactive to mental stress. If these responses are elicited on a regular basis over many years, they might lead to chronic elevation in hs-cTnT concentration.

# **Methods**

Study design. Our study involved participants drawn from the Whitehall II epidemiological cohort (24) for psychophysiological testing between 2006 and 2008. The criteria for entry into the study included no history or objective signs of clinical or subclinical CVD and no previous diagnosis or treatment for hypertension, inflammatory diseases, allergies, or kidney disease. CVD was defined as prior MI, stable or unstable angina, revascularization procedure, heart failure, transient ischemic attack, stroke, or electrocardiographic abnormalities (resting 12-lead electrocardiograms were taken). This information was confirmed by a telephone interview and verified from clinical data collected from the previous 7 phases of the Whitehall II study. Volunteers were of white European origin, aged 53 to 76 years; 56.5% were in full-time employment. Selection was stratified by grade of employment (current or most recent) to include higher and lower socioeconomic status participants. From the initially invited participants (N = 1,169), 27.6% were not eligible (mainly because of prescribed medications) and 25.9% declined to take part. Participants were prohibited from using any antihistamine or anti-inflammatory medication for 7 days before testing and

Abbreviations

were rescheduled if they reported colds or other infections on the day of testing. Participants gave full informed consent to participate in the study, and ethical approval was obtained from the University College London Hospitals Committee on the Ethics of Human Research.

# **Data collection.** PSYCHOPHYSIO-LOGICAL TESTING. We carried out psychophysiological stress testing in either the morning or afternoon in a light temperature-controlled laboratory. This procedure was based on a protocol previously used

in this laboratory (25). Partici-

and Acronyms AMI = acute myocardial infarction BMI = body mass index CAC = coronary artery calcification CRP = C-reactive protein CVD = cardiovascular disease hs-cTnT = high-sensitivity cardiac troponin T IL = interleukin HDL = high-density lipoprotein

LDL = low-density lipoprotein

pants were instructed to refrain from drinking caffeinated beverages and smoking for at least 2 h before the study and not to have performed vigorous physical activity or consumed alcohol the previous evening. After a 30-min rest period, baseline blood pressure (using an automated UA-779 digital monitor [A&D Instruments Ltd., Oxford, United Kingdom]) and a saliva sample were taken. Two behavioral tasks, designed to induce mental stress, were then administered in random order. The tasks were a computerized version of the Stroop task and mirror tracing, both of which have been used extensively in psychophysiological research (26). The tasks each lasted for 5 min. Saliva samples were collected immediately before and after the tasks for the assessment of salivary cortisol. The samples were collected using Salivettes (Sarsted, Leicester, United Kingdom), which were stored at  $-30^{\circ}$ C until analysis. Levels of cortisol were assessed using a time-resolved immunoassay with fluorescence detection at the University of Dresden (Dresden, Germany). The intra-assay and interassay coefficients of variation (CVs) were less than 8%.

CARDIAC TROPONIN T. Nonfasting blood samples were collected in EDTA tubes and centrifuged immediately at 2,500 rpm for 10 min at room temperature. Plasma was removed from the tube and aliquoted into 0.5-ml portions and stored at  $-80^{\circ}$ C until analysis. We measured cTnT concentrations 75 min after the end of the mental stress test using a highly sensitive assay on an automated platform (Elecsys-2010 Troponin T hs STAT, Roche Diagnostics, Haywards Heath, United Kingdom), with a lower detection limit of 3 ng/l and a reported 99th percentile value in apparently healthy individuals of 13.5 ng/l, at which the CV is 9%, confirmed by in-house studies (17–19).

COVARIATES. We assayed baseline plasma interleukin (IL)-6 using a Quantikine high-sensitivity 2-site enzyme-linked immunosorbent assay (ELISA) from R&D Systems (Oxford, United Kingdom). The sensitivity of the assay ranged from 0.016 to 0.110 pg/ml, with intra-assay and interassay CVs of 7.3% and 7.7%, respectively. Baseline C-reactive

protein (CRP) level was measured using a high-sensitivity ELISA (R&D Systems).

CAC was assessed with electron-beam computed tomography (Imatron C-150, General Electric, San Francisco, California) as previously described (27). In brief, 40 contiguous 3-mm slices were obtained during a single breath-hold starting at the carina and proceeding to the level of the diaphragm. Scan time was 100 ms/slice, synchronized to 40% of the R-R interval. Agatston and volumetric calcium scores were calculated to quantify the extent of CAC by a single experienced investigator blinded to the psychophysiological and clinical data on an Aquarius workstation (TeraRecon Inc., San Mateo, California). Because calcified volume was highly correlated with Agatston score (Spearman rho 0.99), we present data for Agatston score only.

Participants reported current smoking levels, weekly alcohol intake (units per week), employment grade (as a marker of social position), and hours of moderate or vigorous physical activity per week. We measured height and weight in light clothing for calculation of body mass index (BMI). Fasting blood samples were taken during a separate clinical assessment. Total and high-density lipoprotein (HDL) cholesterol and triglycerides were measured within 72 h in serum stored at 4°C using enzymatic colorimetric methods (28). Low-density lipoprotein (LDL) cholesterol level was derived using the Friedewald equation (29). Glucose homeostasis was assessed from glycosylated hemoglobin (HbA<sub>1C</sub>) concentration, assayed using boronate affinity chromatography, a combination of boronate affinity and liquid chromatography.

Data analysis. We quantified the cortisol response to stress by subtracting the values of salivary cortisol concentration measured immediately after the behavioral tasks from the baseline. The resulting measure was normally distributed, and it was transformed for the main analyses into a binomial variable using a cut point at the value of 4 nmol/l, which corresponds to the mean value (0.54 nmol/l) + 1 SD (3.47)nmol/l). hs-cTnT was highly right skewed and was undetectable for 83.3% of the sample (below the lower detection limit of 3 ng/l); therefore, it was transformed into a binomial variable (detectable vs. undetectable). Agatston score (CAC) had a right-skewed distribution and was transformed for some analyses into a binomial variable by cutting at the value of zero (0 vs. >0) or 100 (<100 vs.  $\geq$ 100). This threshold was based on the St. Francis Heart Study, which demonstrated maximum sensitivity and specificity for detecting cardiovascular events at a threshold calcium score  $\geq 100$  (30).

We described the study sample according to the exposure (salivary cortisol response to stress tasks) and the outcome (plasma detectable hs-cTnT) variables. Triglyceride and CRP levels had right-skewed distributions and were described using medians and interquartile ranges. Afterward we used multiple logistic regression to model the association between cortisol stress response and odds of detectable hscTnT. Cortisol responses may differ according to baseline cortisol levels and time of testing; therefore, these parameters were included as covariates. We also adjusted for age, sex, employment grade, and smoking because they are related to CVD and may confound the association between cortisol reactivity and CVD. Additionally, we took into account clinical variables that are known to be linked to CVD such as systolic blood pressure, total cholesterol/HDL ratio, and HbA<sub>1c</sub>. Moreover, we adjusted for CRP and IL-6 levels to account for vascular inflammation. Finally, we examined whether the association between cortisol reactivity and hscTnT was independent of underlying coronary atherosclerosis using several approaches: we adjusted for CAC score as a binomial variable using both cut points separately (0 and 100), carried out a subanalysis of participants with no detectable coronary calcification, and carried out a subanalysis of participants with positive CAC scores and in this case further adjusted for CAC score as a log-linear variable.

We carried out sensitivity analyses on cortisol responses by testing several different methods of quantification. To test for dose-response associations, we analyzed the cortisol response as a continuous variable; we tested a different cutoff for binomial analysis, defining positive responses as +0.5 SD instead of 1 SD; we calculated cortisol responses as the ratio between the post-stress and baseline values and tested the resulting variable as a linear variable and in binary analyses using both +1 SD and +0.5 SD as cut points. Additionally, we checked for an association between the baseline levels of salivary cortisol and hs-cTnT using multivariate and timestratified (AM/PM) logistic regression models. As for the multiple adjustments, we further included additional variables such as physical activity, BMI, alcohol consumption, and LDL cholesterol, which were not included in the principal analyses.

# **Results**

A total of 543 participants participated in the study, but 34 (6.3%) had missing information for hs-cTnT and one had an hs-cTnT value >35 ng/l (limit for AMI diagnosis) and were therefore excluded. The final analytic sample comprised 508 participants (mean age of  $62.9 \pm 5.7$  years and 55.1% men). The excluded participants did not differ significantly from the main sample in any covariates. The sample is described according to cortisol stress response in Table 1 and according to hs-cTnT categories in Table 2. The prevalence of detectable hs-cTnT was 16.7%. Older and male participants were more likely to have detectable hscTnT and higher salivary cortisol responses to stress tasks. hs-cTnT, cortisol response, and CAC appeared to be associated with each other: participants with detectable levels of hs-cTnT were more likely to have higher cortisol responses and CAC (Table 2), and participants having high cortisol responses were more likely to have CAC ≥100 (Table 1). Participants with cortisol responses <4 nmol/l were more likely to be smokers, and those with detectable levels of hs-cTnT had higher IL-6 plasma concentrations

Table 1		s of the Study S onse to Laborato		-
		Salivary Corti		
Factor	and Category	<4 nmol/l (n = 459)	$\geq$ 4 nmol/l (n = 35)	p Value*
Age, yrs		62.8 ± 5.6	64.7 ± 6.4	0.055
Male		54.5	71.4	0.056
Laboratory the mo		39.2	41.2	0.823
Current sm	oker	5.5	0.0	<0.001
Latest grad employ				0.071
Higher		38.1	51.4	
Intermed	iate	39.4	37.1	
Lower		22.4	11.4	
Alcohol con	sumption			0.943
No alcoh	ol	15.5	17.1	
Below re- levels	commended	71.2	68.6	
Above re levels	commended	13.3	14.3	
Hours of ph activity	nysical / per week			0.727
< <b>1</b> h		23.3	17.1	
1-4 h		32.4	42.9	
5–7 h		23.3	14.3	
>7 h		21.0	25.7	
Body mass	index, kg/m <sup>2</sup>	$\textbf{25.8} \pm \textbf{3.8}$	$\textbf{25.8} \pm \textbf{4.4}$	0.931
Systolic blo mm H	od pressure, g	$\textbf{128.9} \pm \textbf{15.6}$	$\textbf{130.2} \pm \textbf{15.5}$	0.628
Diastolic bl mm H	ood pressure, g	$\textbf{69.7} \pm \textbf{8.6}$	$\textbf{70.6} \pm \textbf{9.8}$	0.534
Glycosylate	d hemoglobin, %	$\textbf{5.4} \pm \textbf{0.4}$	$\textbf{5.4} \pm \textbf{0.4}$	0.984
Triglyceride	s, g/l	$\textbf{1.2}\pm\textbf{0.7}$	$\textbf{1.1} \pm \textbf{0.7}$	0.480†
HDL, mmol	/I	$\textbf{1.7} \pm \textbf{0.5}$	$\textbf{1.6} \pm \textbf{0.4}$	0.527
LDL, mmol	/1	$\textbf{3.0} \pm \textbf{0.9}$	$\textbf{3.1} \pm \textbf{0.9}$	0.628
Total choles	sterol, mmol/l	$\textbf{5.3} \pm \textbf{0.9}$	$\textbf{5.3} \pm \textbf{0.9}$	0.977
C-reactive p baselir	protein at ne, mg/l	$\textbf{1.0} \pm \textbf{1.4}$	$\textbf{1.1} \pm \textbf{1.0}$	0.780†
IL-6 at base	eline, pg/ml	$\textbf{1.3} \pm \textbf{0.8}$	1.6 $\pm$ 0.9	0.716
Agatston co calciur	oronary n score			0.037
None		44.7	31.4	
<100		32.5	28.6	
<400		14.2	25.7	
≥400		8.7	14.3	
Agatston co score :	oronary calcium >100	22.9	40.0	0.025
hs-cTnT det	ectable (>3 ng/l)	14.8	40.0	<0.001

estadetics of the Chudu C

Values are mean  $\pm$  SD or %. \*p values were computed using univariate logistic regression (Wald test), unless otherwise specified. Ordered categorical variables such as latest grade of employment, alcohol consumption, hours of physical activity per week, and Agatston coronary calcium score were treated as linear. iTwo-sample Wilcoxon rank-sum (Mann-Whitnev) test.

 $\label{eq:hole-sensitivity} \text{HDL} = \text{high-density lipoprotein; hs-cTnT} = \text{high-sensitivity cardiac troponin T; IL} = \text{interleukin; } \text{LDL} = \text{low-density lipoprotein.}$ 

(Tables 1 and 2). Baseline cortisol was not associated with hs-cTnT either in bivariate or multivariate models.

Table 3 shows the results of multiple logistic regression models. We found a robust association between cortisol response and detectable hs-cTnT (odds ratio [OR]: 3.83;

95% confidence interval [CI]: 1.86 to 7.90; p < 0.001). After adjustment for demographic variables and cardiovascular risk factors, the association between cortisol response and detectable hs-cTnT did not differ from that in the unadjusted analysis. After further adjustments for CRP and IL-6, the association remained (OR: 3.98; 95% CI: 1.60 to 9.92; p = 0.003). The adjustment for CAC score as a binary variable did not change the effect estimates. In sensitivity analyses, the results remained unchanged after further adjustment for physical activity, BMI, alcohol consumption, and LDL cholesterol (data not shown). We also performed sensitivity analyses using different approaches to quantify the cortisol stress response, although the same pattern of results emerged. For example, after treating the stress response as a linear proportional change in cortisol, the fully adjusted OR for hs-cTnT was 1.38 (95% CI: 1.10 to 1.73; p = 0.005) for each unit increase in change.

When we restricted the analysis to participants without detectable coronary calcification, the evidence of association remained despite the 40% drop in sample size (n = 222; OR: 4.77; 95% CI: 1.22 to 18.72; p = 0.025). When the analysis was restricted to participants with coronary calcification and adjusted for Agatston CAC score as a log-linear variable, the association between cortisol stress responses and cTnT concentration remained (n = 286; OR: 7.39; 95% CI: 2.22 to 24.64; p = 0.001) (Table 3).

# Discussion

Our results suggest that in healthy participants with no history of CVD, a heightened cortisol response to mental stress is associated with detectable concentrations of circulating cTnT when measured using a high-sensitivity assay. These findings add to previous data from our laboratory that demonstrate an association between cortisol reactivity and CAC (12,13). However, importantly, although this study confirms the findings from other work that stress responsivity is associated with increased CAC (12), the association between cortisol stress responses and circulating cTnT was independent of CAC, a reliable indicator of subclinical coronary atherosclerosis. Therefore, cortisol may be involved in structural and functional adaptations to the heart as well as in the atherosclerotic process.

The prevalence of detectable hs-cTnT in our British sample was 16.7%, which is similar to levels reported (15.7%) in a nationally representative CVD-free population sample in the United States (20). To our knowledge, this is the first study to examine the association between mental stress and cTnT in humans. Our data are consistent with research on stress-induced Takotsubo cardiomyopathy, in which emotional stress increases troponin and cortisol levels in the absence of coronary artery disease (31,32). Our data also agree with those of Caligiuri et al. (33), who showed that mental stress in laboratory animals increases troponin levels. Although stress responses seem to be positively correlated with troponin, evidence for a direct or indirect

#### Table 2

Characteristics of the Study Sample by Categories of hs-cTnT Plasma Concentration

Pactor and CategoryUndetectable (n = 423)Detectable (n = 85)p Vale*hscTnT, ng/1- $5.6 \pm 3.9$ $Age, yrs$ $62.1 \pm 5.1$ $67.2 \pm 6.4$ $<0.001$ Male $51.1$ $75.3$ $<0.001$ Lab session in the morning $39.8$ $35.9$ $0.522$ Current smoker $5.4$ $3.5$ $0.470$ Latest grade of employment- $0.190$ Higher $40.2$ $31.8$ Intermediate $38.5$ $43.5$ Lower $21.3$ $24.7$ Alcohol consumption $0.201$ No alcohol $15.1$ $20.0$ Below recommended $14.0$ $10.6$ levels- $0.481$ Above recommended $14.0$ $10.6$ levels- $0.481$ Hours of physical activity per week- $0.481$ $21.4$ h $33.0$ $32.1$ $5-7$ h $20.2$ $27.4$ Body mass index, kg/m <sup>2</sup> $25.8 \pm 3.9$ $26.2 \pm 3.8$ $0.436$ Systolic blood pressure, mm Hg $69.5 \pm 8.5$ $70.7 \pm 9.7$ $0.262$ Diastolic blood pressure, mm /1 $5.5 \pm 0.4$ $5.5 \pm 0.8$ $0.516$ Tridyperides, g/1 $12 \pm 0.8$ $11 \pm 0.7$ $0.059$ HDL, mmol/1 $3.4 0.8$ $2.9 \pm 0.9$ $0.243$ Salivary cortisol response, mm/1 $0.3 \pm 2.9$ $0.17 \pm 5.5$ $0.004$ Salivary cortisol response, $24 \mod 1.1 \pm 0.7$ $1.2 \pm 3.2$ $0.101$ Salivary cortisol response $\geq 4 \mod 1.1 \pm 0.7$ $0.203$ <th></th> <th>hs-c</th> <th></th>		hs-c		
Age, yr $62.1 \pm 5.1$ $67.2 \pm 6.4$ $<0.001$ Male $51.1$ $75.3$ $<0.001$ Lab session in the morning $39.8$ $35.9$ $0.522$ Current smoker $5.4$ $3.5$ $0.470$ Latest grade of employment $40.2$ $31.8$ $0.190$ Higher $40.2$ $31.8$ $1.51$ $0.190$ Higher $21.3$ $24.7$ $0.201$ $0.301$ Alcohol consumption $15.1$ $20.0$ $0.904$ Below recommended $14.0$ $10.6$ $1.51$ $0.801$ Ievels $14.0$ $10.6$ $1.51$ $0.481$ Above recommended $14.0$ $10.6$ $1.51$ $0.481$ Ievels $14.0$ $10.6$ $1.51$ $0.691$ Hours of physical activity per week $2.58 \pm 3.9$ $26.2 \pm 3.8$ $0.481$ $< 1h$ $23.1$ $22.6$ $1.4$ $0.082$ Ibody mass index, kg/m2 $25.8 \pm 3.9$ $26.2 \pm 3.8$ $0.436$ Systolic blood pressure, mm Hg $69.5 \pm 8.5$ $7.7 \pm 9.7$ $0.262$ Glycosylated hemoglobin, % $5.5 \pm 0.4$ $5.5 \pm 0.8$ $0.516$ Triglycerides, g/1 $1.2 \pm 0.8$ $1.1 \pm 0.7$ $0.021$ Salivary cortisol response, monl/1 $3.5 \pm 0.9$ $1.7 \pm 3.2$ $0.001$ Salivary cortisol response, monl/1 $5.1 \pm 0.7$ $1.2 \pm 3.2$ $0.003$ Salivary cortisol response, monl/1 $1.3 \pm 0.8$ $1.6 \pm 0.9$ $0.003$ Salivary cortisol response, monl/1 $1.3 \pm 0.8$ $1$	Factor and Category			p Value*
Male         51.1         75.3         <0.001           Lab session in the morning         39.8         35.9         0.522           Current smoker         5.4         3.5         0.470           Latest grade of employment         0.190         1         1.8           Intermediate         38.5         43.5         0.201           Alcohol consumption         0.201         0.201           No alcohol         15.1         20.0         20.0           Below recommended         70.9         69.4         1.8           ievels         0.401         0.6         1.4           Hours of physical activity per week         0.481         2.6           <1 h	hs-cTnT, ng/l	_	$\textbf{5.6} \pm \textbf{3.9}$	
Lab session in the morning         39.8         35.9         0.522           Current smoker         5.4         3.5         0.470           Latest grade of employment         40.2         31.8           Higher         40.2         31.8           Intermediate         38.5         43.5           Lower         21.3         24.7           Alcohol consumption         0.201         No alcohol         15.1         20.0           No alcohol         15.1         20.0         69.4         levels           Above recommended         70.9         69.4         levels           Above recommended         14.0         10.6         levels           -<1h	Age, yrs	$\textbf{62.1} \pm \textbf{5.1}$	$\textbf{67.2} \pm \textbf{6.4}$	<0.001
Current smoker5.43.50.470Latest grade of employment0.190Higher40.231.8Intermediate38.543.5Lower21.324.7Alcohol consumption0.201No alcohol15.120.0Below recommended14.010.6levels14.010.6Hours of physical activity per week0.481<1.4 h	Male	51.1	75.3	<0.001
Latest grade of employment         Intermediate         3.18         Intermediate           Higher         40.2         31.8         1.8           Intermediate         38.5         43.5         1.000           Lower         21.3         24.7         20.01           No alcohol         15.1         20.0         20.01           Below recommended         70.9         69.4         20.01           Hours of physical activity per week         0.481         21.0         22.6           1-4 h         33.0         32.1         25.7         0.481           57 h         20.2         27.4         0.082           Body mass index, kg/m <sup>2</sup> 25.8 ± 3.9         26.2 ± 3.8         0.436           Systolic blood pressure, mm Hg         69.5 ± 8.5         70.7 ± 9.7         0.262           Glycosylated hemoglobin, %         5.5 ± 0.4         5.5 ± 0.8         0.516           Trid cholesterol, mmol/1         1.7 ± 0.5         1.6 ± 0.4         0.293           Glycosylated hemoglobin,	Lab session in the morning	39.8	35.9	0.522
Higher lintermediate40.231.8Intermediate38.543.5Lower21.324.7Alcohol consumption15.120.0No alcohol15.120.0Below recommended70.969.4levels14.010.6Hours of physical activity per week23.122.61-4 h33.032.15-7 h20.227.4Body mass index, kg/m²25.8 ± 3.926.2 ± 3.80.436Systolic blood pressure, mm Hg128.5 ± 15.3131.8 ± 17.40.062Diastolic blood pressure, mm Hg69.5 ± 8.570.7 ± 9.70.262Glycosylated hemoglobin, %5.5 ± 0.45.5 ± 0.80.516Triglycerides, g/11.2 ± 0.81.1 ± 0.70.0591HDL, mmol/13 ± 0.82.9 ± 0.90.243Total cholesterol, mmol/15.3 ± 0.95.1 ± 1.00.024Salivary cortisol at baseline, nmol/16.5 ± 4.47 ± 4.20.321Salivary cortisol response, nmol/10.3 ± 0.81.6 ± 0.90.003Salivary cortisol response, nmol/11.0 ± 2.71.2 ± 3.20.1011L6 at baseline, mg/ml1.3 ± 0.81.6 ± 0.90.003Agatston coronary calcium score32.926.24.004.6Agatston coronary calcium score47.325.94.001Agatston coronary calcium score6.623.54.001Agatston coronary calcium score1.9.945.94.0.01 <t< td=""><td>Current smoker</td><td>5.4</td><td>3.5</td><td>0.470</td></t<>	Current smoker	5.4	3.5	0.470
Intermediate         38.5         43.5           Lower         21.3         24.7           Alcohol consumption         15.1         20.0           No alcohol         15.1         20.0           Below recommended         70.9         69.4           levels         14.0         10.6           Above recommended         14.0         10.6           levels         21.3         22.6           1-4 h         33.0         32.1           5-7 h         23.8         17.9           >7 h         20.2         27.4           Body mass index, kg/m2         25.8 ± 3.9         26.2 ± 3.8         0.436           Systolic blood pressure, mm Hg         69.5 ± 8.5         70.7 ± 9.7         0.262           Glycosylated hemoglobin, %         5.5 ± 0.4         5.5 ± 0.8         0.516           Total cholesterol, mmol/1         1.2 ± 0.8         1.1 ± 0.7         0.059           JUbL, mmol/1         3 ± 0.8         2.9 ± 0.9         0.243           Salivary cortisol response, nmol/1         5.3 ± 0.9         5.1 ± 1.0         0.024           Salivary cortisol response, nmol/1         5.3 ± 0.9         5.1 ± 0.0         0.243           Intermolitie         1.0 ± 2.7 <td>Latest grade of employment</td> <td></td> <td></td> <td>0.190</td>	Latest grade of employment			0.190
Lower21.324.7Alcohol consumption15.120.0No alcohol15.120.0Below recommended levels70.969.4Hours of physical activity per week14.010.614.023.122.61-4 h33.032.15-7 h20.227.48ody mass index, kg/m²25.8 ± 3.926.2 ± 3.89xystolic blood pressure, mm Hg69.5 ± 8.570.7 ± 9.710istolic blood pressure, 	Higher	40.2	31.8	
Alcohol consumption         0.201           No alcohol         15.1         20.0           Below recommended levels         70.9         69.4           Above recommended levels         14.0         10.6           Hours of physical activity per week         2.1         2.6           <1.h	Intermediate	38.5	43.5	
No alcohol15.120.0Below recommended levels70.969.4Above recommended levels14.010.6Hours of physical activity per week20.48121.122.6 $4.1$ h23.122.61-4 h33.032.15-7 h23.817.9>7 h20.227.4Body mass index, kg/m <sup>2</sup> 25.8 ± 3.926.2 ± 3.80.43610.95 ± 5.5131.8 ± 17.40.082Systolic blood pressure, mm Hg69.5 ± 8.570.7 ± 9.70.20227.40.262Body mass index, kg/m <sup>2</sup> 25.8 ± 3.926.2 ± 3.80.4361128.5 ± 15.3131.8 ± 17.40.0820.10112.2 ± 0.81.1 ± 0.70.2621011.7 ± 0.51.6 ± 0.40.2931011.7 ± 0.51.6 ± 0.40.2931021.1 ± 0.71.0 ± 0.710.0241013 ± 0.82.9 ± 0.90.2431021.1 ± 0.51.6 ± 0.40.2931021.1 ± 0.51.6 ± 0.40.2931021.1 ± 0.51.6 ± 0.40.2931031.5 ± 0.47 ± 4.20.3211041.5 ± 0.47 ± 4.20.3211055.11.7 ± 5.50.0011281.0 ± 2.71.2 ± 3.20.1011291.3 ± 0.81.6 ± 0.90.00312928.22.928.210032.928.210032.928.2 </td <td>Lower</td> <td>21.3</td> <td>24.7</td> <td></td>	Lower	21.3	24.7	
Below recommended levels         70.9         69.4           Above recommended levels         14.0         10.6           Hours of physical activity per week         8         8           <1 h	Alcohol consumption			0.201
levels         14.0         10.6           Above recommended levels         14.0         10.6           Hours of physical activity per week         0.481           <1 h	No alcohol	15.1	20.0	
levelsHours of physical activity per week0.481<1h		70.9	69.4	
per week23.122.6 $-4 h$ 33.032.1 $5-7 h$ 23.817.9 $>7 h$ 20.227.4Body mass index, kg/m²25.8 ± 3.926.2 ± 3.80.436Systolic blood pressure, mm Hg128.5 ± 15.3131.8 ± 17.40.082Diastolic blood pressure, mm Hg $69.5 \pm 8.5$ $70.7 \pm 9.7$ 0.262Glycosylated hemoglobin,% $5.5 \pm 0.4$ $5.5 \pm 0.8$ 0.516Triglycerides, g/1 $1.2 \pm 0.8$ $1.1 \pm 0.7$ 0.0597HDL, mmol/1 $1.7 \pm 0.5$ $1.6 \pm 0.4$ 0.293LDL, mmol/1 $3 \pm 0.8$ $2.9 \pm 0.9$ 0.243Total cholesterol, mmol/1 $5.3 \pm 0.9$ $5.1 \pm 1.0$ 0.024Salivary cortisol a baseline, mmol/1 $6.5 \pm 4.4$ $7 \pm 4.2$ 0.321Salivary cortisol response, mmol/1 $1.0 \pm 2.7$ $1.2 \pm 3.2$ $0.101 \ddagger$ baseline, mg/1L-6 at baseline, pg/ml $1.3 \pm 0.8$ $1.6 \pm 0.9$ 0.003Agatston coronary calcium score $32.9$ $28.2$ <		14.0	10.6	
1-4 h33.032.15-7 h23.817.9>7 h20.227.4Body mass index, kg/m²25.8 ± 3.926.2 ± 3.80.436Systolic blood pressure, mm Hg128.5 ± 15.3131.8 ± 17.40.082Diastolic blood pressure, mm Hg $69.5 \pm 8.5$ $70.7 \pm 9.7$ 0.262Glycosylated hemoglobin, % $5.5 \pm 0.4$ $5.5 \pm 0.8$ 0.516Triglycerides, g/1 $1.2 \pm 0.8$ $1.1 \pm 0.7$ 0.059†HDL, mmol/1 $1.7 \pm 0.5$ $1.6 \pm 0.4$ 0.293LDL, mmol/1 $3 \pm 0.8$ $2.9 \pm 0.9$ 0.243Total cholesterol, mmol/1 $5.3 \pm 0.9$ $5.1 \pm 1.0$ 0.024Salivary cortisol response, mmol/1 $0.3 \pm 2.9$ $1.7 \pm 5.5$ $0.004$ Salivary cortisol response, nmol/1 $1.0 \pm 2.7$ $1.2 \pm 3.2$ $0.101^{+}$ L-6 at baseline, pg/ml $1.3 \pm 0.8$ $1.6 \pm 0.9$ $0.003$ Agatston coronary calcium score $32.9$ $28.2$ $<400$ Agatston coronary calcium $32.9$ $28.2$ $<400$ $6.6$ $23.5$				0.481
5-7 h       23.8       17.9         >7 h       20.2       27.4         Body mass index, kg/m²       25.8 ± 3.9       26.2 ± 3.8       0.436         Systolic blood pressure, mm Hg       128.5 ± 15.3       131.8 ± 17.4       0.082         Diastolic blood pressure, mm Hg       69.5 ± 8.5       70.7 ± 9.7       0.262         Glycosylated hemoglobin, %       5.5 ± 0.4       5.5 ± 0.8       0.516         Triglycerides, g/l       1.2 ± 0.8       1.1 ± 0.7       0.0591         HDL, mmol/l       1.7 ± 0.5       1.6 ± 0.4       0.293         ILDI, mmol/l       3 ± 0.8       2.9 ± 0.9       0.243         Total cholesterol, mmol/l       5.3 ± 0.9       5.1 ± 1.0       0.024         Salivary cortisol at baseline, mmol/l       5.3 ± 0.9       5.1 ± 1.0       0.024         Salivary cortisol response, nmmol/l       5.1       1.7 ± 4.2       0.321         Salivary cortisol response, nmmol/l       5.1       1.7 ± 1.2 ± 3.2       0.004         response ≥4 nmol/l       1.3 ± 0.8       1.6 ± 0.9       0.003         IL-6 at baseline, pg/ml       1.3 ± 0.8       1.6 ± 0.9       0.001         Score       None       47.3       25.9       <100	< <b>1</b> h	23.1	22.6	
$>7 h$ 20.2       27.4         Body mass index, kg/m²       25.8 ± 3.9       26.2 ± 3.8       0.436         Systolic blood pressure, mm Hg       128.5 ± 15.3       131.8 ± 17.4       0.082         Diastolic blood pressure, mm Hg $69.5 \pm 8.5$ $70.7 \pm 9.7$ 0.262         Glycosylated hemoglobin, % $5.5 \pm 0.4$ $5.5 \pm 0.8$ 0.516         Triglycerides, g/l $1.2 \pm 0.8$ $1.1 \pm 0.7$ 0.059†         HDL, mmol/l $1.7 \pm 0.5$ $1.6 \pm 0.4$ 0.293         ILDL, mmol/l $3 \pm 0.8$ $2.9 \pm 0.9$ 0.243         Total cholesterol, mmol/l $5.3 \pm 0.9$ $5.1 \pm 1.0$ 0.024         Salivary cortisol at baseline, $6.5 \pm 4.4$ $7 \pm 4.2$ 0.321         mmol/l $5.1$ $17.1$ $<0.001$ Salivary cortisol response, $1.0 \pm 2.7$ $1.2 \pm 3.2$ $0.101^{+}$ baseline, mg/l $1.0 \pm 2.7$ $1.2 \pm 3.2$ $0.003$ IL-6 at baseline, pg/ml $1.3 \pm 0.8$ $1.6 \pm 0.9$ $0.003$ Agatston coronary calcium score $<0.001$ $<0.001$ $<0.001$ Score       None $47.3$ $25.9$ $<0.001$ $<0.001$ </td <td>1–4 h</td> <td>33.0</td> <td>32.1</td> <td></td>	1–4 h	33.0	32.1	
Body mass index, kg/m <sup>2</sup> 25.8 $\pm$ 3.9         26.2 $\pm$ 3.8         0.436           Systolic blood pressure, mm Hg         128.5 $\pm$ 15.3         131.8 $\pm$ 17.4         0.082           Diastolic blood pressure, mm Hg         69.5 $\pm$ 8.5         70.7 $\pm$ 9.7         0.262           Glycosylated hemoglobin, %         5.5 $\pm$ 0.4         5.5 $\pm$ 0.8         0.516           Triglycerides, g/l         1.2 $\pm$ 0.8         1.1 $\pm$ 0.7         0.059 <sup>†</sup> HDL, mmol/l         1.7 $\pm$ 0.5         1.6 $\pm$ 0.4         0.293           LDL, mmol/l         3 $\pm$ 0.8         2.9 $\pm$ 0.9         0.243           Total cholesterol, mmol/l         5.3 $\pm$ 0.9         5.1 $\pm$ 1.0         0.024           Salivary cortisol at baseline, nmol/l         6.5 $\pm$ 4.4         7 $\pm$ 4.2         0.321           Salivary cortisol response, nmol/l         0.3 $\pm$ 2.9         1.7 $\pm$ 5.5         0.004           Salivary cortisol response, nmol/l         1.0 $\pm$ 2.7         1.2 $\pm$ 3.2         0.101 <sup>†</sup> Salivary cortisol response         1.3 $\pm$ 0.8         1.6 $\pm$ 0.9         0.003           Restine, mg/l         1.3 $\pm$ 0.8         1.6 $\pm$ 0.9         0.001           L6 at baseline, pg/ml         1.3 $\pm$ 0.8         1.6 $\pm$ 0.9         0.001           score	5–7 h	23.8	17.9	
Systolic blood pressure, mm Hg       128.5 ± 15.3       131.8 ± 17.4       0.082         Diastolic blood pressure, mm Hg $69.5 \pm 8.5$ $70.7 \pm 9.7$ $0.262$ Glycosylated hemoglobin,% $5.5 \pm 0.4$ $5.5 \pm 0.8$ $0.516$ Triglycerides, g/l $1.2 \pm 0.8$ $1.1 \pm 0.7$ $0.059^{\dagger}$ HDL, mmol/l $1.7 \pm 0.5$ $1.6 \pm 0.4$ $0.293$ LDL, mmol/l $3 \pm 0.8$ $2.9 \pm 0.9$ $0.243$ Total cholesterol, mmol/l $5.3 \pm 0.9$ $5.1 \pm 1.0$ $0.024$ Salivary cortisol at baseline, $6.5 \pm 4.4$ $7 \pm 4.2$ $0.321$ nmol/l $5.1$ $17.1$ $<0.001$ Salivary cortisol response, $1.0 \pm 2.7$ $1.2 \pm 3.2$ $0.101^{\dagger}$ Salivary cortisol response, $24$ nmol/l $1.3 \pm 0.8$ $1.6 \pm 0.9$ $0.003$ Salivary cortisol response, $24$ nmol/l $1.0 \pm 2.7$ $1.2 \pm 3.2$ $0.101^{\dagger}$ baseline, mg/l $1.3 \pm 0.8$ $1.6 \pm 0.9$ $0.003$ IL-6 at baseline, pg/ml $1.3 \pm 0.8$ $1.6 \pm 0.9$ $0.003$ Agatston coronary calcium score $<0.001$ $<2.9$ $<2.0$ None	>7 h	20.2	27.4	
mm Hg       69.5 ± 8.5       70.7 ± 9.7       0.262         mm Hg $5.5 \pm 0.4$ $5.5 \pm 0.8$ 0.516         Glycosylated hemoglobin,% $5.5 \pm 0.4$ $5.5 \pm 0.8$ 0.516         Triglycerides, g/l $1.2 \pm 0.8$ $1.1 \pm 0.7$ 0.059†         HDL, mmol/l $1.7 \pm 0.5$ $1.6 \pm 0.4$ 0.293         LDL, mmol/l $3 \pm 0.8$ $2.9 \pm 0.9$ 0.243         Total cholesterol, mmol/l $5.3 \pm 0.9$ $5.1 \pm 1.0$ 0.024         Salivary cortisol at baseline, $6.5 \pm 4.4$ $7 \pm 4.2$ 0.321         nmol/l $5.1$ $1.7 \pm 5.5$ 0.004         Salivary cortisol response, $1.0 \pm 2.7$ $1.2 \pm 3.2$ $0.101^{\dagger}$ baseline, mg/l $1.3 \pm 0.8$ $1.6 \pm 0.9$ $0.003$ IL-6 at baseline, pg/ml $1.3 \pm 0.8$ $1.6 \pm 0.9$ $0.003$ Agatston coronary calcium score $<0.001$ $<0.001$ $<0.001$ None $47.3$ $25.9$ $<0.001$ $<0.001$ $32.9$ $28.2$ $<0.001$ $<0.001$ $32.9$ $28.2$ $<400$ $6.6$ $23.5$ Agatston coronary	Body mass index, kg/m <sup>2</sup>	$\textbf{25.8} \pm \textbf{3.9}$	$\textbf{26.2} \pm \textbf{3.8}$	0.436
mm Hg           Glycosylated hemoglobin, % $5.5 \pm 0.4$ $5.5 \pm 0.8$ $0.516$ Triglycerides, g/1 $1.2 \pm 0.8$ $1.1 \pm 0.7$ $0.059$ HDL, mmol/1 $1.7 \pm 0.5$ $1.6 \pm 0.4$ $0.293$ LDL, mmol/1 $3 \pm 0.8$ $2.9 \pm 0.9$ $0.243$ Total cholesterol, mmol/1 $5.3 \pm 0.9$ $5.1 \pm 1.0$ $0.024$ Salivary cortisol at baseline, $6.5 \pm 4.4$ $7 \pm 4.2$ $0.321$ Salivary cortisol response, nmol/1 $0.3 \pm 2.9$ $1.7 \pm 5.5$ $0.004$ Salivary cortisol response, nmol/1 $5.1$ $17.1$ $<0.001$ Salivary cortisol response, nmol/1 $1.0 \pm 2.7$ $1.2 \pm 3.2$ $0.101^{\pm}$ Creactive protein at baseline, mg/1 $1.3 \pm 0.8$ $1.6 \pm 0.9$ $0.003$ LE at baseline, pg/ml $1.3 \pm 0.8$ $1.6 \pm 0.9$ $0.001^{\pm}$ score $\sqrt{1.00}$ $32.9$ $28.2$ $\sqrt{100}$ $32.9$ $28.2$ $\sqrt{400}$ $32.5$ $\sqrt{100}$ $32.9$ $28.2$ $\sqrt{400}$ $\sqrt{20.01}$ $\sqrt{20.01}$		$\textbf{128.5} \pm \textbf{15.3}$	$\textbf{131.8} \pm \textbf{17.4}$	0.082
$\begin{array}{ c c c c } \mbox{Triglycerides, g/l} & 1.2 \pm 0.8 & 1.1 \pm 0.7 & 0.059^{\dagger} \\ \mbox{HDL, mmol/l} & 1.7 \pm 0.5 & 1.6 \pm 0.4 & 0.293 \\ \mbox{LDL, mmol/l} & 3 \pm 0.8 & 2.9 \pm 0.9 & 0.243 \\ \mbox{Total cholesterol, mmol/l} & 5.3 \pm 0.9 & 5.1 \pm 1.0 & 0.024 \\ \mbox{Salivary cortisol at baseline, } & 6.5 \pm 4.4 & 7 \pm 4.2 & 0.321 \\ \mbox{nmol/l} & 0.3 \pm 2.9 & 1.7 \pm 5.5 & 0.004 \\ \mbox{nmol/l} & 5.1 & 17.1 & <0.001 \\ \mbox{response} \geq 4 \mbox{nmol/l} & 1.0 \pm 2.7 & 1.2 \pm 3.2 & 0.101^{\dagger} \\ \mbox{baseline, mg/l} & 1.3 \pm 0.8 & 1.6 \pm 0.9 & 0.003 \\ \mbox{Agatston coronary calcium} & 47.3 & 25.9 \\ $		$\textbf{69.5} \pm \textbf{8.5}$	$\textbf{70.7} \pm \textbf{9.7}$	0.262
HDL, mmol/l       1.7 ± 0.5       1.6 ± 0.4       0.293         HDL, mmol/l       3 ± 0.8       2.9 ± 0.9       0.243         Total cholesterol, mmol/l       5.3 ± 0.9       5.1 ± 1.0       0.024         Salivary cortisol at baseline, nmol/l $6.5 \pm 4.4$ $7 \pm 4.2$ 0.321         Salivary cortisol response, nmol/l $0.3 \pm 2.9$ $1.7 \pm 5.5$ 0.004         Salivary cortisol response, nmol/l $5.1$ $17.1$ <0.001	Glycosylated hemoglobin, %	$\textbf{5.5} \pm \textbf{0.4}$	$\textbf{5.5} \pm \textbf{0.8}$	0.516
$\begin{array}{ c c c c } LDL, mmol/l & 3 \pm 0.8 & 2.9 \pm 0.9 & 0.243 \\ \hline \mbox{Total cholesterol, mmol/l} & 5.3 \pm 0.9 & 5.1 \pm 1.0 & 0.024 \\ \hline \mbox{Salivary cortisol at baseline, } & 6.5 \pm 4.4 & 7 \pm 4.2 & 0.321 \\ mmol/l & & & & & & & & & & & & & & & & & & $	Triglycerides, g/l	$\textbf{1.2} \pm \textbf{0.8}$	$\textbf{1.1} \pm \textbf{0.7}$	0.059†
Total cholesterol, mmol/l $5.3 \pm 0.9$ $5.1 \pm 1.0$ $0.024$ Salivary cortisol at baseline, mmol/l $6.5 \pm 4.4$ $7 \pm 4.2$ $0.321$ Salivary cortisol response, nmol/l $0.3 \pm 2.9$ $1.7 \pm 5.5$ $0.004$ Salivary cortisol response, nmol/l $0.3 \pm 2.9$ $1.7 \pm 5.5$ $0.004$ Salivary cortisol response $\geq 4$ nmol/l $5.1$ $17.1$ $<0.001$ Salivary cortisol response $\geq 4$ nmol/l $1.0 \pm 2.7$ $1.2 \pm 3.2$ $0.101^{\dagger}$ Creactive protein at baseline, mg/l $1.0 \pm 2.7$ $1.2 \pm 3.2$ $0.003$ IL-6 at baseline, pg/ml $1.3 \pm 0.8$ $1.6 \pm 0.9$ $0.003$ Agatston coronary calcium score $<0.001$ $<0.001$ $<0.001$ None $47.3$ $25.9$ $<0.001$ $<0.001$ $<100$ $32.9$ $28.2$ $<0.001$ $<0.001$ $<0.001$ $32.9$ $28.2$ $<0.001$ $<0.001$ $<0.001$ $<0.001$ $<0.001$ $<0.001$ $<0.001$ $<0.001$ $<0.001$ $<0.001$ $<0.001$ $<0.001$ $<0.001$ $<0.001$ $<0.001$ $<0.001$ $<0.00$	HDL, mmol/l	$\textbf{1.7} \pm \textbf{0.5}$	$\textbf{1.6} \pm \textbf{0.4}$	0.293
	LDL, mmol/l	$3\pm0.8$	$\textbf{2.9} \pm \textbf{0.9}$	0.243
nmol/l $0.3 \pm 2.9$ $1.7 \pm 5.5$ $0.004$ Salivary cortisol response, nmol/l $5.1$ $1.7 \pm 5.5$ $0.004$ Salivary cortisol response $\geq 4$ nmol/l $5.1$ $17.1$ $<0.001$ Creactive protein at baseline, mg/l $1.0 \pm 2.7$ $1.2 \pm 3.2$ $0.101^{\dagger}$ IL-6 at baseline, mg/l $1.3 \pm 0.8$ $1.6 \pm 0.9$ $0.003$ Agatston coronary calcium score $<0.001$ $<0.001$ None $47.3$ $25.9$ $<0.001$ $<100$ $32.9$ $28.2$ $<0.001$ $<400$ $13.2$ $22.4$ $<2400$ $6.6$ $23.5$ Agatston coronary calcium $19.9$ $45.9$ $<0.001$	Total cholesterol, mmol/l	$\textbf{5.3} \pm \textbf{0.9}$	$\textbf{5.1} \pm \textbf{1.0}$	0.024
nmol/l       5.1       17.1       <0.001         Salivary cortisol response $\geq 4$ nmol/l       1.0 ± 2.7       1.2 ± 3.2       0.101†         C-reactive protein at baseline, mg/l       1.0 ± 2.7       1.2 ± 3.2       0.003         IL-6 at baseline, pg/ml       1.3 ± 0.8       1.6 ± 0.9       0.003         Agatston coronary calcium score            None       47.3       25.9          <100	-	$\textbf{6.5} \pm \textbf{4.4}$	$7\pm4.2$	0.321
response $\geq 4$ nmol/l         C-reactive protein at baseline, mg/l       1.0 $\pm$ 2.7       1.2 $\pm$ 3.2       0.101†         IL-6 at baseline, mg/l       1.3 $\pm$ 0.8       1.6 $\pm$ 0.9       0.003         Agatston coronary calcium score       <       <       <       <       <       <         None       47.3       25.9       <       <       <		$\textbf{0.3} \pm \textbf{2.9}$	$\textbf{1.7} \pm \textbf{5.5}$	0.004
IL-6 at baseline, pg/ml         I.3 ± 0.8         I.6 ± 0.9         0.003           Agatston coronary calcium score         <0.001	•	5.1	17.1	<0.001
Agatston coronary calcium score         <0.001           None         47.3         25.9           <100	·	$\textbf{1.0} \pm \textbf{2.7}$	$\textbf{1.2}\pm\textbf{3.2}$	0.101†
score         47.3         25.9           None         47.3         25.9           <100	IL-6 at baseline, pg/ml	$\textbf{1.3} \pm \textbf{0.8}$	$\textbf{1.6} \pm \textbf{0.9}$	0.003
<100				<0.001
<400         13.2         22.4           ≥400         6.6         23.5           Agatston coronary calcium         19.9         45.9         <0.001	None	47.3	25.9	
≥400 6.6 23.5 Agatston coronary calcium 19.9 45.9 <0.001	<100	32.9	28.2	
Agatston coronary calcium 19.9 45.9 <0.001	<400	13.2	22.4	
5	≥400	6.6	23.5	
		19.9	45.9	<0.001

Values are mean  $\pm$  SD or %. \*p values were computed using univariate logistic regression (Wald test), unless otherwise specified. Ordered categorical variables such as latest grade of employment, alcohol consumption, hours of physical activity per week, and Agatston coronary calcium score were treated as linear. †Two-sample Wilcoxon rank-sum (Mann-Whitney) test. Abbreviations as in Table 1.

glucocorticoid modulation of troponin is still scarce. The troponin gene contains a transcription factor binding site (34,35), previously shown to bind the activated glucocorticoid receptor (36). Despite the presence of this binding site,

the effect of glucocorticoids on troponin levels does not seem to be via direct modulation of gene expression (37–41).

Cortisol has a strong diurnal pattern that can cause difficulties in the interpretation of the data; we dealt with this issue by considering stress response as the difference between the post-test and pre-test measurements and by adjusting for cortisol baseline level and day and time of testing at the data analysis stage. We also performed sensitivity analyses using different approaches to quantify the cortisol stress response, although the same pattern of results emerged. It is possible that the cortisol response to stress contributes to the increased levels of troponin T observed here by several indirect mechanisms. First, oxidative stress could play a role in cortisolinduced troponin release (42,43). Supporting this hypothesis, the temporal change in serum troponin levels matches the increase in the concentration of myocardial malondialdehyde, a marker of free radical lipid peroxidation (44). Second, stressinduced cortisol levels could increase troponin levels by modulating ion channels. For example, dexamethasone, a synthetic glucocorticoid, significantly increases the L-type  $Ca^{2+}$  currents in neonatal rat cardiomyocytes (45) and accelerates myocyte spontaneous contractions (46). Finally, cortisol responses to stress could induce troponin levels by potentiation of adrenergic signaling. Corticosteroids potentiate adrenergic signaling and increase muscle contraction and cardiomyocyte hypertrophy (47). Corticosteroid-potentiated adrenergic signaling increases mineralocorticoid and glucocorticoid receptor expression and function in cardiomyocytes (47).

Detectable hs-cTnT is associated with noncardiac conditions such as severe renal disease (48,49), and theoretically, our results could be due to confounding if patients with renal disease are more likely to test positive on mental stress tests. However, it is unlikely that this mechanism underlies our results because the study participants were free from any chronic conditions at the time of testing, as explained in the Methods section.

The effect of stress-related cortisol release on cardiomyocytes may be mediated by atherosclerosis and consequent ischemia, although the adjustments for CAC, which is a recognized index of atherosclerosis, did not attenuate the findings. CAC and hs-cTnT do not appear to lie on the same causal pathway because their effect was not diminished by mutual adjustment, despite being correlated with each other. Thus, cortisol might have acted through indirect effects as described previously.

Noncalcified coronary plaques are not detectable using cardiac computed tomography, and that may partly explain why CAC did not attenuate the association between cortisol and hs-cTnT. However, there is a direct relationship between the number of calcified plaques present and total plaque burden, and CAC correlates highly with the severity of coronary artery disease; therefore, the absence of calcification implies that there is probably little significant coronary artery disease (50). On the other hand, it has been argued that raised troponin T levels may be due to occult or undetected plaque rupture (51), and it is known that plaque

Table 3

Multiple Logistic Regression Models for the Association Between Salivary Cortisol Response to Standard Laboratory Mental Stress Tasks (Binary Exposure) and Plasma Detectable hs-cTnT (Binary Outcome)

Model for Detectable hs-cTnT (Outcome)	OR for Cortisol Response (Exposure)	p Value	95% CI
1. Crude association	3.83	<0.001	1.86-7.90
2. Adjusted for baseline salivary cortisol (pre-task) and time of the session (AM or PM)	3.68	0.001	1.75-7.76
3. With further adjustment for age and sex	2.75	0.021	1.16-6.49
4. With further adjustment for latest grade of employment and smoking	2.95	0.014	1.25-7.00
<ol> <li>With further adjustment for systolic blood pressure, total cholesterol/HDL ratio, and glycosylated hemoglobin</li> </ol>	3.63	0.005	1.49-8.83
6. With further adjustment for CRP and IL-6	3.98	0.003	1.60-9.92
7a. With further adjustment for coronary calcification score, treated as a binary variable with cutoff at 0	3.98	0.003	1.59-9.95
7b. Same as model 7a but with cutoff set at 100	3.97	0.003	1.59-9.91
7c. Model 6 was restricted to participants without coronary calcification (CAC score 0, n = 222)	4.77	0.025	1.22-18.72
7d. Model 6 was restricted to participants with coronary calcification (CAC score $>$ 0, n = 286), for which score it was further adjusted using a log-linear variable	7.39	0.001	2.22-24.64

CAC = coronary artery calcification; CRP = C-reactive protein; OR = odds ratio; other abbreviations as in Table 1.

rupture is a relatively common event that is usually not followed by an acute cardiac event (52). This process may have operated in our patients with minimal CAC score levels and detectable hs-cTnT.

A single measure of plasma hs-cTnT concentration cannot be regarded as a robust test if it is not stable in time (i.e., if it shows remarkable intraindividual short-term variation). However, the results from the ARIC (Atherosclerosis Risk in Communities) study showed that hs-cTnT intraindividual variability over 6 weeks is almost null, with a correlation coefficient of 0.94 (53). Thus, although our study collected hs-cTnT after a brief and moderately stressful behavioral challenge, it is improbable that troponin T was released in response to this task. To the contrary, we hypothesized that high cortisol responders are individuals who are hyperreactive to mental stress in everyday life. If these responses are elicited on a regular basis over extended periods of time, they might lead to chronic elevations in hs-cTnT concentrations.

This was a cross-sectional study, and therefore, we cannot determine the causal sequence. Heightened cortisol stress responsivity may contribute to early signs of CVD, or people at an early stage of cardiac disease may be more prone to disturbed stress responses. In fact, cardiac troponins are the most sensitive and specific biochemical markers of myocardial damage (54), but their elevation can be due to a variety of reasons such as pericarditis, myocarditis, pulmonary embolism, and others (55). However, it is unlikely that the undetected presence of those conditions can explain our findings because no participants reported any symptoms or signs of cardiac disease; had any previous diagnosis of or treatment for hypertension, inflammatory disease, or allergies; and did not show any electrocardiographic indications of congenital heart disease on tests carried out over more than 20 years in the Whitehall II study. Moreover, we found a strong association in people with and without coronary calcification, which is consistent with another study showing that hs-cTnT is predictive of

CVD in healthy people and of secondary events in patients with CVD (56). It is interesting to note that detectable levels of hs-cTnT were associated with salivary cortisol response to stress test but not with its baseline levels (pretest), corroborating its relationship with stress-induced neuroendocrine dysregulation.

## Conclusions

Heightened cortisol responses to mental stress were associated with detectable levels of cTnT using high-sensitivity assays in the plasma of healthy people. Heightened stressinduced cortisol release may increase the risk of CHD through several pathways, including atherosclerotic processes, or other indirect effects on the cardiomyocytes. Further research is needed to understand the role of psychosocial stress in the pathophysiology of cardiac cell damage.

### Acknowledgments

The authors acknowledge the contributions of Sir Professor Michael Marmot to the study design and Dr. Yoichi Chida, Dr. Romano Endrighi, Bev Murray, Dr. Katie O'Donnell, Livia Urbanova, and Cecily Walker to the data collection.

**Reprint requests and correspondence:** Dr. Antonio Lazzarino, University College of London, Department of Epidemiology and Public Health, 1-19 Torrington Place, London WC1E 6BT, United Kingdom. E-mail: a.lazzarino@ucl.ac.uk.

#### REFERENCES

- Brotman DJ, Golden SH, Wittstein IS. The cardiovascular toll of stress. Lancet 2007;370:1089–100.
- Steptoe A, Kivimäki M. Stress and cardiovascular disease. Nat Rev Cardiol 2012;9:360–70.
- Surtees PG, Wainwright NWJ, Luben RN, Wareham NJ, Bingham SA, Khaw K-T. Psychological distress, major depressive disorder, and risk of stroke. Neurology 2008;70:788–94.

- 4. Steptoe A, Vögele C. Methodology of mental stress testing in cardiovascular research. Circulation 1991;83:II14-24.
- Dimsdale JE. Psychological stress and cardiovascular disease. J Am Coll Cardiol 2008;51:1237–46.
- 6. Chrousos GP, Kino T. Glucocorticoid action networks and complex psychiatric and/or somatic disorders. Stress 2007;10:213–9.
- Dekker MJHJ, Koper JW, van Aken MO, et al. Salivary cortisol is related to atherosclerosis of carotid arteries. J Clin Endocrinol Metab 2008;93:3741–7.
- Mihailidou AS, Loan Le TY, Mardini M, Funder JW. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 2009;54:1306–12.
- Kumari M, Shipley M, Stafford M, Kivimaki M. Association of diurnal patterns in salivary cortisol with all-cause and cardiovascular mortality: findings from the Whitehall II study. J Clin Endocrinol Metab 2011; 96:1478–85.
- Vogelzangs N, Beekman ATF, Milaneschi Y, Bandinelli S, Ferrucci L, Penninx BWJH. Urinary cortisol and six-year risk of all-cause and cardiovascular mortality. J Clin Endocrinol Metab 2010;95:4959–64.
- Yamaji M, Tsutamoto T, Kawahara C, et al. Serum cortisol as a useful predictor of cardiac events in patients with chronic heart failure: the impact of oxidative stress. Circ Heart Fail 2009;2:608–15.
- Hamer M, O'Donnell K, Lahiri A, Steptoe A. Salivary cortisol responses to mental stress are associated with coronary artery calcification in healthy men and women. Eur Heart J 2010;31:424–9.
- Hamer M, Endrighi R, Venuraju SM, Lahiri A, Steptoe A. Cortisol responses to mental stress and the progression of coronary artery calcification in healthy men and women. PLoS One 2012;7:e31356.
- Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation 2007;116:2634–53.
- Myocardial infarction redefined—a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000;21:1502–13.
- Wallace TW, Abdullah SM, Drazner MH, et al. Prevalence and determinants of troponin T elevation in the general population. Circulation 2006;113:1958–65.
- Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem 2010;56:254–61.
- 18. Collinson PO. Sensitive troponin assays. J Clin Pathol 2011;64:845-9.
- 19. Collinson PO, Heung YM, Gaze D, et al. Influence of population selection on the 99th percentile reference value for cardiac troponin assays. Clin Chem 2012;58:219–25.
- De Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010;304:2503–12.
- deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 2010;304:2494–502.
- Devereaux PJ, Chan MTV, Alonso-Coello P, et al. Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA 2012;307:2295–304.
- Cramer GE, Brouwer MA, Vader HL, et al. Highly sensitive cardiac troponin T and long-term mortality in a population of communityderived perimenopausal women: nested case-control study. Heart 2013;99:528–33.
- Marmot MG, Smith GD, Stansfeld S, et al. Health inequalities among British civil servants: the Whitehall II study. Lancet 1991;337:1387–93.
- Steptoe A, Owen N, Kunz-Ebrecht S, Mohamed-Ali V. Inflammatory cytokines, socioeconomic status, and acute stress responsivity. Brain Behav Immun 2002;16:774–84.
- Goldberg AD, Becker LC, Bonsall R, et al. Ischemic, hemodynamic, and neurohormonal responses to mental and exercise stress. Experience from the Psychophysiological Investigations of Myocardial Ischemia Study (PIMI). Circulation 1996;94:2402–9.
- Anand DV, Lim E, Darko D, et al. Determinants of progression of coronary artery calcification in type 2 diabetes: role of glycemic control and inflammatory/vascular calcification markers. J Am Coll Cardiol 2007;50:2218–25.
- Brunner EJ, Marmot MG, Nanchahal K, et al. Social inequality in coronary risk: central obesity and the metabolic syndrome. Evidence from the Whitehall II study. Diabetologia 1997;40:1341–9.

- Warnick GR, Knopp RH, Fitzpatrick V, Branson L. Estimating lowdensity lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. Clin Chem 1990;36:15–9.
- Arad Y, Goodman KJ, Roth M, Newstein D, Guerci AD. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. J Am Coll Cardiol 2005;46:158–65.
- Beydoun SR, Wang J, Levine RL, Farvid A. Emotional stress as a trigger of myasthenic crisis and concomitant Takotsubo cardiomyopathy: a case report. J Med Case Rep 2010;4:393.
- Wittstein IS, Thiemann DR, Lima JAC, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med 2005;352:539–48.
- Caligiuri G, Levy B, Pernow J, Thorén P, Hansson GK. Myocardial infarction mediated by endothelin receptor signaling in hypercholesterolemic mice. Proc Natl Acad Sci U S A 1999;96:6920–4.
- Bassel-Duby R, Grohe CM, Jessen ME, et al. Sequence elements required for transcriptional activity of the human myoglobin promoter in intact myocardium. Circ Res 1993;73:360–6.
- Christensen TH, Prentice H, Gahlmann R, Kedes L. Regulation of the human cardiac/slow-twitch troponin C gene by multiple, cooperative, cell-type-specific, and MyoD-responsive elements. Mol Cell Biol 1993; 13:6752–65.
- Schüle R, Muller M, Otsuka-Murakami H, Renkawitz R. Cooperativity of the glucocorticoid receptor and the CACCC-box binding factor. Nature 1988;332:87–90.
- Chen QM, Alexander D, Sun H, et al. Corticosteroids inhibit cell death induced by doxorubicin in cardiomyocytes: induction of antiapoptosis, antioxidant, and detoxification genes. Mol Pharmacol 2005; 67:1861–73.
- Fejes-Tóth G, Náray-Fejes-Tóth A. Early aldosterone-regulated genes in cardiomyocytes: clues to cardiac remodeling? Endocrinology 2007; 148:1502–10.
- Liu L, Walker EA, Kissane S, et al. Gene expression and miR profiles of human corneal fibroblasts in response to dexamethasone. Invest Ophthalmol Vis Sci 2011;52:7282–8.
- Muller O, Pradervand S, Berger S, et al. Identification of corticosteroid-regulated genes in cardiomyocytes by serial analysis of gene expression. Genomics 2007;89:370–7.
- Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD. Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res 2004;64:1757–64.
- Costantini D, Marasco V, Møller AP. A meta-analysis of glucocorticoids as modulators of oxidative stress in vertebrates. J Comp Physiol B Biochem Syst Environ Physiol 2011;181:447–56.
- Neumayr G, Pfister R, Mitterbauer G, et al. Effect of the "Race Across The Alps" in elite cyclists on plasma cardiac troponins I and T. Am J Cardiol 2002;89:484–6.
- Nie J, Close G, George KP, Tong TK, Shi Q. Temporal association of elevations in serum cardiac troponin T and myocardial oxidative stress after prolonged exercise in rats. Eur J Appl Physiol 2010;110: 1299–303.
- 45. Whitehurst RM Jr., Zhang M, Bhattacharjee A, Li M. Dexamethasoneinduced hypertrophy in rat neonatal cardiac myocytes involves an elevated L-type Ca<sup>2+</sup> current. J Mol Cell Cardiol 1999;31:1551–8.
- Maturana A, Lenglet S, Python M, Kuroda S, Rossier MF. Role of the T-type calcium channel CaV3.2 in the chronotropic action of corticosteroids in isolated rat ventricular myocytes. Endocrinology 2009; 150:3726–34.
- Lister K, Autelitano DJ, Jenkins A, Hannan RD, Sheppard KE. Cross talk between corticosteroids and alpha-adrenergic signalling augments cardiomyocyte hypertrophy: a possible role for SGK1. Cardiovasc Res 2006;70:555–65.
- Sharma R, Gaze DC, Pellerin D, et al. Cardiac structural and functional abnormalities in end stage renal disease patients with elevated cardiac troponin T. Heart 2006;92:804–9.
- 49. Irfan A, Twerenbold R, Reiter M, et al. Determinants of highsensitivity troponin T among patients with a noncardiac cause of chest pain. Am J Med 2012;125:491–8.
- Arad Y, Spadaro LA, Goodman K, Newstein D, Guerci AD. Prediction of coronary events with electron beam computed tomography. J Am Coll Cardiol 2000;36:1253–60.

- Korosoglou G, Lehrke S, Mueller D, et al. Determinants of troponin release in patients with stable coronary artery disease: insights from CT angiography characteristics of atherosclerotic plaque. Heart 2011;97: 823–31.
- 52. Arbab-Zadeh A, Nakano M, Virmani R, Fuster V. Acute coronary events. Circulation 2012;125:1147–56.
- Agarwal SK, Avery CL, Ballantyne CM, et al. Sources of variability in measurements of cardiac troponin T in a community-based sample: the Atherosclerosis Risk in Communities study. Clin Chem 2011;57: 891–7.
- 54. Jaffe AS, Ravkilde J, Roberts R, et al. It's time for a change to a troponin standard. Circulation 2000;102:1216–20.
- 55. Roongsritong C, Warraich I, Bradley C. Common causes of troponin elevations in the absence of acute myocardial infarction: incidence and clinical significance. Chest 2004;125:1877–84.
- Beatty AL, Ku IA, Christenson RH, Defilippi CR, Schiller NB, Whooley MA. High-sensitivity cardiac troponin T levels and secondary events in outpatients with coronary heart disease from the Heart and Soul study. JAMA Intern Med 2013;173:763–9.

**Key Words:** atherosclerotic plaque • computed tomography • myocardial infarction • psychological stress • troponin T.